Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

70 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Selective CDK7 Inhibition Suppresses Cell Cycle Progression and MYC Signaling While Enhancing Apoptosis in Therapy-resistant Estrogen Receptor-positive Breast Cancer.
Guarducci C, Nardone A, Russo D, Nagy Z, Heraud C, Grinshpun A, Zhang Q, Freelander A, Leventhal MJ, Feit A, Cohen Feit G, Feiglin A, Liu W, Hermida-Prado F, Kesten N, Ma W, De Angelis C, Morlando A, O'Donnell M, Naumenko S, Huang S, Nguyen QD, Huang Y, Malorni L, Bergholz JS, Zhao JJ, Fraenkel E, Lim E, Schiff R, Shapiro GI, Jeselsohn R. Guarducci C, et al. Among authors: jeselsohn r. Clin Cancer Res. 2024 May 1;30(9):1889-1905. doi: 10.1158/1078-0432.CCR-23-2975. Clin Cancer Res. 2024. PMID: 38381406 Free PMC article.
Estrogen Receptor Mutations as Novel Targets for Immunotherapy in Metastatic Estrogen Receptor-positive Breast Cancer.
Goldberg J, Qiao N, Guerriero JL, Gross B, Meneksedag Y, Lu YF, Philips AV, Rahman T, Meric-Bernstam F, Roszik J, Chen K, Jeselsohn R, Tolaney SM, Peoples GE, Alatrash G, Mittendorf EA. Goldberg J, et al. Among authors: jeselsohn r. Cancer Res Commun. 2024 Feb 22;4(2):496-504. doi: 10.1158/2767-9764.CRC-23-0244. Cancer Res Commun. 2024. PMID: 38335301 Free PMC article.
Author Correction: Comprehensive genomic characterization of HER2-low and HER2-0 breast cancer.
Tarantino P, Gupta H, Hughes ME, Files J, Strauss S, Kirkner G, Feeney AM, Li Y, Garrido-Castro AC, Barroso-Sousa R, Bychkovsky BL, DiLascio S, Sholl L, MacConaill L, Lindeman N, Johnson BE, Meyerson M, Jeselsohn R, Qiu X, Li R, Long H, Winer EP, Dillon D, Curigliano G, Cherniack AD, Tolaney SM, Lin NU. Tarantino P, et al. Among authors: jeselsohn r. Nat Commun. 2023 Dec 14;14(1):8321. doi: 10.1038/s41467-023-44124-y. Nat Commun. 2023. PMID: 38097580 Free PMC article. No abstract available.
Comprehensive genomic characterization of HER2-low and HER2-0 breast cancer.
Tarantino P, Gupta H, Hughes ME, Files J, Strauss S, Kirkner G, Feeney AM, Li Y, Garrido-Castro AC, Barroso-Sousa R, Bychkovsky BL, DiLascio S, Sholl L, MacConaill L, Lindeman N, Johnson BE, Meyerson M, Jeselsohn R, Qiu X, Li R, Long H, Winer EP, Dillon D, Curigliano G, Cherniack AD, Tolaney SM, Lin NU. Tarantino P, et al. Among authors: jeselsohn r. Nat Commun. 2023 Nov 18;14(1):7496. doi: 10.1038/s41467-023-43324-w. Nat Commun. 2023. PMID: 37980405 Free PMC article.
Mathematical Modeling Identifies Optimum Palbociclib-fulvestrant Dose Administration Schedules for the Treatment of Patients with Estrogen Receptor-positive Breast Cancer.
Cheng YC, Stein S, Nardone A, Liu W, Ma W, Cohen G, Guarducci C, McDonald TO, Jeselsohn R, Michor F. Cheng YC, et al. Among authors: jeselsohn r. Cancer Res Commun. 2023 Nov 16;3(11):2331-2344. doi: 10.1158/2767-9764.CRC-23-0257. Cancer Res Commun. 2023. PMID: 37921419 Free PMC article.
Author Correction: Dose escalation and expansion cohorts in patients with advanced breast cancer in a Phase I study of the CDK7-inhibitor samuraciclib.
Coombes RC, Howell S, Lord SR, Kenny L, Mansi J, Mitri Z, Palmieri C, Chap LI, Richards P, Gradishar W, Sardesai S, Melear J, O'Shaughnessy J, Ward P, Chalasani P, Arkenau T, Baird RD, Jeselsohn R, Ali S, Clack G, Bahl A, McIntosh S, Krebs MG. Coombes RC, et al. Among authors: jeselsohn r. Nat Commun. 2023 Aug 7;14(1):4741. doi: 10.1038/s41467-023-40561-x. Nat Commun. 2023. PMID: 37550302 Free PMC article. No abstract available.
Identification of an Imidazopyridine-based Compound as an Oral Selective Estrogen Receptor Degrader for Breast Cancer Therapy.
Pan M, Solozobova V, Kuznik NC, Jung N, Gräßle S, Gourain V, Heneka YM, Cramer von Clausbruch CA, Fuhr O, Munuganti RSN, Maddalo D, Blattner C, Neeb A, Sharp A, Cato L, Weiss C, Jeselsohn RM, Orian-Rousseau V, Bräse S, Cato ACB. Pan M, et al. Among authors: jeselsohn rm. Cancer Res Commun. 2023 Jul 27;3(7):1378-1396. doi: 10.1158/2767-9764.CRC-23-0111. eCollection 2023 Jul. Cancer Res Commun. 2023. PMID: 37520743 Free PMC article.
Dose escalation and expansion cohorts in patients with advanced breast cancer in a Phase I study of the CDK7-inhibitor samuraciclib.
Coombes RC, Howell S, Lord SR, Kenny L, Mansi J, Mitri Z, Palmieri C, Chap LI, Richards P, Gradishar W, Sardesai S, Melear J, O'Shaughnessy J, Ward P, Chalasani P, Arkenau T, Baird RD, Jeselsohn R, Ali S, Clack G, Bahl A, McIntosh S, Krebs MG. Coombes RC, et al. Among authors: jeselsohn r. Nat Commun. 2023 Jul 24;14(1):4444. doi: 10.1038/s41467-023-40061-y. Nat Commun. 2023. PMID: 37488191 Free PMC article. Clinical Trial.
70 results